



Rehovot, Israel, 17th December 2020

Press Release

BioView and INL spin-off RUBYnanomed start collaboration to improve cancer diagnostics

The International Iberian Nanotechnology Laboratory – INL, its spin-off RUBYnanomed, (Braga, Portugal) a promising company in the field of liquid biopsy, and BioView Ltd., from Rehovot Israel (TASE:BIOV) a provider of automated cell imaging and analysis solutions, announce their collaboration for the development of a custom imaging solution to accelerate the deployment of their circulating tumour cell (CTC) technology in the clinic, in the framework of the CTC-OD project funded by “la Caixa” Foundation.

The collaboration combines RUBYnanomed’s technology, the RUBYchip™ that provides highly efficient isolation of CTCs from blood samples of cancer patients, and BioView’s Duet imaging and analysis system, which streamlines the otherwise challenging process of CTC detection and analysis. These CTCs are responsible of the metastatic process, and their analysis provide real-time information about cancer progression, enabling the prediction of disease aggressiveness and resistance to therapy. The combination of these two technologies provides an extraordinarily efficient, automated, standardised, high-throughput, high-capacity solution to study CTCs in the clinic.

RUBYnanomed’s Founders team and members of the Medical Devices Research Group at INL, commented: “The integration of BioView’s imaging technology in our workflow for CTC analysis will help us to automatically classify cancer cells that are immobilised in our system. The automation enables an unprecedented sample-to-result turnaround from days to just a few hours, facilitating more frequent patient monitoring and stratification”.

BioView Ltd. President and CEO, Dr. Alan Schwebel, commented:

We are very excited to collaborate with INL and RUBYnanomed to help advance CTC S2A (sample-to-answer) solutions to the clinical laboratory. We believe that the integration of this cutting-edge enrichment technology and BioView’s state-of-the-art CTC imaging and analysis capabilities is an important milestone in our vision to standardize CTC Liquid Biopsy downstream analysis”.

* The combined imaging solution and the RUBYchip™ are currently used for research purposes only but, with the support of the CaixaImpulse program, we expect to start official clinical trials for regulatory approval in 2022.

**The project leading to these results has received funding and support from the “la Caixa” Foundation under CaixaImpulse Grant LCF/TR/CC20/52480003.

Caixa*impulse*

 **“la Caixa” Foundation**



About INL www.inl.int

INL, the International Iberian Nanotechnology Laboratory, is the first, and so far the only, fully international research organization in Europe in the field of nanoscience and nanotechnology. INL is an international intergovernmental research organization (IGRO) with the mission to perform cutting-edge research and development in interdisciplinary nanotechnology and to function as an innovation integrator in multiple application domains. INL was created under an international legal framework similar to that of other International Research organizations like CERN, EMBL or ESA and with the aim to become a global centre of excellence in applied nanotechnology research. The centre provides a high-tech research environment to address major challenges of Nanotechnologies, in four main areas: Health, Safety in Environmental and Food control, Renewable Energy, Information and Communication Technologies.

The Precise Personalised HealthTech Cluster of INL works at the interface between Engineering and Medicine, by developing novel nano-enabled Medical Technologies in collaboration with hospitals that can provide significant advantages for the prevention, earlier diagnosis, and personalized treatment of diseases.

About RUBYnanomed www.rubynanomed.com

RUBYnanomed is a recently founded startup devoting its activities to non-invasive progression monitoring of cancer. RUBYnanomed has developed and can manufacture the RUBYchip™, a microfluidic device for isolating all types of CTCs. This device has demonstrated the ability to isolate a higher number of CTCs comparing with the reference equipment and the potential to provide improved correlation with clinical prognostic information. During 2016 and 2017 this innovation project started its path participating and winning several innovation and technology transfer programs at European and national level. Incorporated in 2018, RUBYnanomed has since participated in international roadshows and received support from several international well-reputed research and innovation programs, including EC H2020, Royal Society of Chemistry, HKSTP EPiC, Caixa Impulse among others, to achieve further pre-clinical validation of the technology.

About BioView Ltd www.bioview.com

For nearly two decades BioView has been developing, manufacturing and marketing innovative automated cell imaging and analysis solutions, for use in cytology, cytogenetic, pathology clinical and research laboratories. Founded and managed by experts in the areas of medical devices, clinical and research applications, and automated scanning systems, BioView leverages its knowledge and expertise in the development of a dedicated scanner, designed to address the specific challenges of CTC imaging, analysis and reporting.

BioView is a publicly traded company on the Tel Aviv Stock exchange, and currently has strategic collaborations underway with international scientific leaders and institutions. For more information about the BioView technology, and press related issues, please contact info@bioview.co.il or visit our website at www.bioview.com

*** This article only reflects the partners view and LCBF is not responsible for any use that may be made of the information that it contains.